A Cuker

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis
    Adam Cuker
    Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Blood 120:4160-7. 2012
  2. ncbi Unfractionated heparin for the treatment of venous thromboembolism: best practices and areas of uncertainty
    Adam Cuker
    Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Semin Thromb Hemost 38:593-9. 2012
  3. ncbi How I treat heparin-induced thrombocytopenia
    Adam Cuker
    Departments of Medicine, University of Pennsylvania, Philadelphia, USA
    Blood 119:2209-18. 2012
  4. ncbi Current and emerging therapeutics for heparin-induced thrombocytopenia
    Adam Cuker
    Department of Medicine and Pathology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Semin Thromb Hemost 38:31-7. 2012
  5. ncbi A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
    Adam Cuker
    Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Blood 118:6299-305. 2011
  6. ncbi Recent advances in heparin-induced thrombocytopenia
    Adam Cuker
    Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Curr Opin Hematol 18:315-22. 2011
  7. ncbi Heparin-induced thrombocytopenia: present and future
    Adam Cuker
    Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    J Thromb Thrombolysis 31:353-66. 2011
  8. ncbi Evidence-based mini-review: Is indium-labeled autologous platelet scanning predictive of response to splenectomy in patients with chronic immune thrombocytopenia?
    Adam Cuker
    Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Hematology Am Soc Hematol Educ Program 2010:385-6. 2010
  9. ncbi Immune thrombocytopenia
    Adam Cuker
    Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Hematology Am Soc Hematol Educ Program 2010:377-84. 2010
  10. ncbi The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion
    A Cuker
    University of Pennsylvania, Philadelphia, PA Duke University, Durham, NC, USA
    J Thromb Haemost 8:2642-50. 2010

Collaborators

Detail Information

Publications16

  1. ncbi Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis
    Adam Cuker
    Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Blood 120:4160-7. 2012
    ..14 (0.09-0.22) and 0.64 (0.40-0.82), respectively. A low probability 4Ts score appears to be a robust means of excluding HIT. Patients with intermediate and high probability scores require further evaluation...
  2. ncbi Unfractionated heparin for the treatment of venous thromboembolism: best practices and areas of uncertainty
    Adam Cuker
    Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Semin Thromb Hemost 38:593-9. 2012
    ..This review will critically examine the evidence for dosing and laboratory monitoring of UFH in the management of VTE, and highlight areas of uncertainty and future research...
  3. ncbi How I treat heparin-induced thrombocytopenia
    Adam Cuker
    Departments of Medicine, University of Pennsylvania, Philadelphia, USA
    Blood 119:2209-18. 2012
    ..In addition, we propose areas of investigation for improvement of the diagnosis and management of this potentially fatal disorder...
  4. ncbi Current and emerging therapeutics for heparin-induced thrombocytopenia
    Adam Cuker
    Department of Medicine and Pathology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Semin Thromb Hemost 38:31-7. 2012
    ..The objectives of this review are to discuss currently available drugs for the treatment of HIT, highlight the limitations of these agents, and examine future therapies...
  5. ncbi A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
    Adam Cuker
    Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Blood 118:6299-305. 2011
    ..Clinicians should maintain a high level of vigilance and consider routine monitoring for ITP in patients treated with this agent. This trial was registered at www.clinicaltrials.gov as #NCT00050778...
  6. ncbi Recent advances in heparin-induced thrombocytopenia
    Adam Cuker
    Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Curr Opin Hematol 18:315-22. 2011
    ..The objective of this review is to examine recent advances and highlight areas of future inquiry in the epidemiology, diagnosis, and management of this potentially fatal disorder...
  7. ncbi Heparin-induced thrombocytopenia: present and future
    Adam Cuker
    Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    J Thromb Thrombolysis 31:353-66. 2011
    ..Nevertheless, critical questions remain unanswered. The objective of this review is to examine our current understanding of the epidemiology, pathophysiology, diagnosis, and management of HIT and to highlight areas of future inquiry...
  8. ncbi Evidence-based mini-review: Is indium-labeled autologous platelet scanning predictive of response to splenectomy in patients with chronic immune thrombocytopenia?
    Adam Cuker
    Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Hematology Am Soc Hematol Educ Program 2010:385-6. 2010
    ..The patient asks if there are any means by which to predict likelihood of response to splenectomy. You have heard about the use of indium-labeled autologous platelet scanning for this purpose and wonder what the evidence shows...
  9. ncbi Immune thrombocytopenia
    Adam Cuker
    Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Hematology Am Soc Hematol Educ Program 2010:377-84. 2010
    ..Recent studies suggest the potential for aggressive therapy at the time of diagnosis to alter the natural history of ITP and point to the importance of quality-of-life considerations in therapeutic decision making...
  10. ncbi The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion
    A Cuker
    University of Pennsylvania, Philadelphia, PA Duke University, Durham, NC, USA
    J Thromb Haemost 8:2642-50. 2010
    ..The diagnosis of heparin-induced thrombocytopenia (HIT) is challenging. Over-diagnosis and over-treatment are common...
  11. ncbi Interlaboratory variation in heparin monitoring: Lessons from the Quality Management Program of Ontario coagulation surveys
    Adam Cuker
    University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Thromb Haemost 104:837-44. 2010
    ..0% vs. 10.5%) and 2007 (15.0% vs. 11.6%) surveys. Substantial interlaboratory variation in UFH monitoring, both between and within APTT methods, was observed and was not reduced by use of an anti-Xa assay...
  12. ncbi Toxicities of the thrombopoietic growth factors
    Adam Cuker
    Department of Medicine and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Semin Hematol 47:289-98. 2010
    ..The incidence and clinical implications of these toxicities as well as strategies for patient safety monitoring are examined...
  13. ncbi Safety of the thrombopoiesis-stimulating agents for the treatment of immune thrombocytopenia
    Adam Cuker
    Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Curr Drug Saf 5:171-81. 2010
    ..The incidence and severity of these toxicities as well as strategies for monitoring patient safety and pharmacovigilance are discussed...
  14. ncbi Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time
    A Cuker
    Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    J Thromb Haemost 7:80-6. 2009
    ..Whether and to what extent this approach enhances the interlaboratory agreement of UFH monitoring has not been reported...
  15. ncbi Contemporary management of primary immune thrombocytopenia in adults
    S Lakshmanan
    Department of Medicine Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
    J Thromb Haemost 10:1988-98. 2012
    ..In the absence of such data, we do not favor a single second-line approach for all patients. Rather, we consider the pros and cons of each option with our patients and engage them in the decision-making process...
  16. ncbi Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease
    A D Metjian
    Penn Comprehensive Hemophilia and Thrombosis Program, Division of Hematology Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Haemophilia 15:918-25. 2009
    ..This study documents the strong bleeding phenotype in severe VWD and provides data to help target therapy, including prophylaxis, for patients most at risk of bleeding complications...